U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease Brea NeriNovember 9, 2018 Facebook0 Twitter LinkedIn0 StumbleUpon Reddit Tumblr 0 Likes